A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
Public ClinicalTrials.gov record NCT05470387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of LB1148 in Accelerating the Time to Return of Bowel Function in Subjects Undergoing Planned Bowel Resection (INTEGRITY)
Study identification
- NCT ID
- NCT05470387
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Palisade Bio
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- LB1148 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2022
- Primary completion
- Mar 5, 2023
- Completion
- Aug 10, 2023
- Last update posted
- Jun 12, 2024
2022 – 2023
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 315 | Mobile | Alabama | 36617 | — |
| Site 354 | La Jolla | California | 92037 | — |
| Site 329 | Orange | California | 92868 | — |
| Site 350 | San Diego | California | 92123 | — |
| Site 312 | Torrance | California | 90502 | — |
| Site 359 | Bridgeport | Connecticut | 06610 | — |
| Site 351 | Clearwater | Florida | 33756 | — |
| Site 358 | Jacksonville | Florida | 32224 | — |
| Site 331 | Miami | Florida | 33136 | — |
| Site 357 | Iowa City | Iowa | 52242 | — |
| Site 321 | Baltimore | Maryland | 21237 | — |
| Site 324 | Burlington | Massachusetts | 01805 | — |
| Site 355 | Grand Rapids | Michigan | 49503 | — |
| Site 325 | Rochester | Minnesota | 55905 | — |
| Site 352 | St Louis | Missouri | 63110 | — |
| Site 317 | New York | New York | 10029 | — |
| Site 356 | New York | New York | 10032 | — |
| Site 318 | Chapel Hill | North Carolina | 27599 | — |
| Site 313 | Columbus | Ohio | 43210 | — |
| Site 353 | Providence | Rhode Island | 02906 | — |
| Site 320 | Dallas | Texas | 75390 | — |
| Site 319 | Houston | Texas | 77030 | — |
| Site 326 | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05470387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05470387 live on ClinicalTrials.gov.